JP2018516851A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018516851A5 JP2018516851A5 JP2017550548A JP2017550548A JP2018516851A5 JP 2018516851 A5 JP2018516851 A5 JP 2018516851A5 JP 2017550548 A JP2017550548 A JP 2017550548A JP 2017550548 A JP2017550548 A JP 2017550548A JP 2018516851 A5 JP2018516851 A5 JP 2018516851A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- antibody
- formula
- integer
- here
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims description 247
- 238000000034 method Methods 0.000 claims description 82
- 125000003545 alkoxy group Chemical group 0.000 claims description 52
- 125000000217 alkyl group Chemical group 0.000 claims description 50
- 125000005843 halogen group Chemical group 0.000 claims description 48
- 238000009739 binding Methods 0.000 claims description 43
- 230000027455 binding Effects 0.000 claims description 42
- 125000001188 haloalkyl group Chemical group 0.000 claims description 40
- 125000000732 arylene group Chemical group 0.000 claims description 22
- 125000005549 heteroarylene group Chemical group 0.000 claims description 22
- 229960001230 asparagine Drugs 0.000 claims description 21
- 125000005647 linker group Chemical group 0.000 claims description 20
- 125000004438 haloalkoxy group Chemical group 0.000 claims description 19
- 150000001413 amino acids Chemical group 0.000 claims description 18
- 125000003342 alkenyl group Chemical group 0.000 claims description 17
- 125000002877 alkyl aryl group Chemical group 0.000 claims description 17
- 125000000304 alkynyl group Chemical group 0.000 claims description 17
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 17
- 125000003118 aryl group Chemical group 0.000 claims description 17
- 150000001540 azides Chemical class 0.000 claims description 17
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 17
- 125000001072 heteroaryl group Chemical group 0.000 claims description 17
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 17
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 17
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Substances CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 15
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 13
- 125000000404 glutamine group Chemical group N[C@@H](CCC(N)=O)C(=O)* 0.000 claims description 12
- 125000004404 heteroalkyl group Chemical group 0.000 claims description 12
- 125000006850 spacer group Chemical group 0.000 claims description 12
- 239000008194 pharmaceutical composition Substances 0.000 claims description 11
- 206010028980 Neoplasm Diseases 0.000 claims description 10
- 239000000562 conjugate Substances 0.000 claims description 10
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical group [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 8
- 201000011510 cancer Diseases 0.000 claims description 8
- 239000003638 chemical reducing agent Substances 0.000 claims description 8
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 8
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 8
- 150000001408 amides Chemical class 0.000 claims description 6
- 230000015572 biosynthetic process Effects 0.000 claims description 6
- 229960002173 citrulline Drugs 0.000 claims description 6
- 150000003839 salts Chemical class 0.000 claims description 6
- 238000003786 synthesis reaction Methods 0.000 claims description 6
- 239000004474 valine Substances 0.000 claims description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 6
- 239000000611 antibody drug conjugate Substances 0.000 claims description 5
- 229940049595 antibody-drug conjugate Drugs 0.000 claims description 5
- 235000018417 cysteine Nutrition 0.000 claims description 5
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 5
- 229920001481 poly(stearyl methacrylate) Polymers 0.000 claims description 5
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims description 4
- 108060008539 Transglutaminase Proteins 0.000 claims description 4
- 239000002253 acid Substances 0.000 claims description 4
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 claims description 4
- 230000002062 proliferating effect Effects 0.000 claims description 4
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims description 4
- 102000003601 transglutaminase Human genes 0.000 claims description 4
- 239000011701 zinc Substances 0.000 claims description 4
- 229910052725 zinc Inorganic materials 0.000 claims description 4
- NDDSIUHFLJACFT-VWURTLBMSA-N (2s)-2-amino-3-phenylpropanoic acid;(2s)-2,4-diamino-4-oxobutanoic acid Chemical compound OC(=O)[C@@H](N)CC(N)=O.OC(=O)[C@@H](N)CC1=CC=CC=C1 NDDSIUHFLJACFT-VWURTLBMSA-N 0.000 claims description 3
- ALBODLTZUXKBGZ-JUUVMNCLSA-N (2s)-2-amino-3-phenylpropanoic acid;(2s)-2,6-diaminohexanoic acid Chemical compound NCCCC[C@H](N)C(O)=O.OC(=O)[C@@H](N)CC1=CC=CC=C1 ALBODLTZUXKBGZ-JUUVMNCLSA-N 0.000 claims description 3
- UGCWVVMCHYLGBO-DQZFIDPSSA-N (2s,3s)-2-amino-3-methylpentanoic acid;(2s)-2,4-diamino-4-oxobutanoic acid Chemical compound CC[C@H](C)[C@H](N)C(O)=O.OC(=O)[C@@H](N)CC(N)=O UGCWVVMCHYLGBO-DQZFIDPSSA-N 0.000 claims description 3
- FZUBHJJEYNHYFU-DKWTVANSSA-N 2-aminoacetic acid;(2s)-2,4-diamino-4-oxobutanoic acid Chemical compound NCC(O)=O.OC(=O)[C@@H](N)CC(N)=O FZUBHJJEYNHYFU-DKWTVANSSA-N 0.000 claims description 3
- 239000004471 Glycine Substances 0.000 claims description 3
- 239000004473 Threonine Substances 0.000 claims description 3
- 230000021615 conjugation Effects 0.000 claims description 3
- 229960000310 isoleucine Drugs 0.000 claims description 3
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 claims description 2
- DVLFYONBTKHTER-UHFFFAOYSA-N 3-(N-morpholino)propanesulfonic acid Chemical compound OS(=O)(=O)CCCN1CCOCC1 DVLFYONBTKHTER-UHFFFAOYSA-N 0.000 claims description 2
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 claims description 2
- 239000007995 HEPES buffer Substances 0.000 claims description 2
- 239000007993 MOPS buffer Substances 0.000 claims description 2
- 108010090665 Mannosyl-Glycoprotein Endo-beta-N-Acetylglucosaminidase Proteins 0.000 claims description 2
- 229910019142 PO4 Inorganic materials 0.000 claims description 2
- 102000000447 Peptide-N4-(N-acetyl-beta-glucosaminyl) Asparagine Amidase Human genes 0.000 claims description 2
- 108010055817 Peptide-N4-(N-acetyl-beta-glucosaminyl) Asparagine Amidase Proteins 0.000 claims description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 2
- 125000002947 alkylene group Chemical group 0.000 claims description 2
- 239000007975 buffered saline Substances 0.000 claims description 2
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 2
- 125000001153 fluoro group Chemical group F* 0.000 claims description 2
- 235000019253 formic acid Nutrition 0.000 claims description 2
- -1 linker compound Chemical class 0.000 claims description 2
- 150000002894 organic compounds Chemical class 0.000 claims description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 2
- 239000010452 phosphate Substances 0.000 claims description 2
- 239000011780 sodium chloride Substances 0.000 claims description 2
- 239000002904 solvent Substances 0.000 claims description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 claims description 2
- 239000000427 antigen Substances 0.000 claims 30
- 108091007433 antigens Proteins 0.000 claims 30
- 102000036639 antigens Human genes 0.000 claims 30
- 239000012634 fragment Substances 0.000 claims 30
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 4
- 206010017758 gastric cancer Diseases 0.000 claims 4
- 201000011549 stomach cancer Diseases 0.000 claims 4
- 206010006187 Breast cancer Diseases 0.000 claims 3
- 208000026310 Breast neoplasm Diseases 0.000 claims 3
- 206010033128 Ovarian cancer Diseases 0.000 claims 3
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 3
- 206010060862 Prostate cancer Diseases 0.000 claims 3
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 3
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 claims 3
- 208000035475 disorder Diseases 0.000 claims 3
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 2
- 206010018338 Glioma Diseases 0.000 claims 2
- 208000034578 Multiple myelomas Diseases 0.000 claims 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 2
- 208000006265 Renal cell carcinoma Diseases 0.000 claims 2
- 206010041067 Small cell lung cancer Diseases 0.000 claims 2
- 125000000539 amino acid group Chemical group 0.000 claims 2
- 230000003321 amplification Effects 0.000 claims 2
- 201000010536 head and neck cancer Diseases 0.000 claims 2
- 208000014829 head and neck neoplasm Diseases 0.000 claims 2
- 208000029824 high grade glioma Diseases 0.000 claims 2
- 229910052739 hydrogen Inorganic materials 0.000 claims 2
- 239000001257 hydrogen Substances 0.000 claims 2
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims 2
- 201000010893 malignant breast melanoma Diseases 0.000 claims 2
- 201000011614 malignant glioma Diseases 0.000 claims 2
- 208000006178 malignant mesothelioma Diseases 0.000 claims 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 2
- 238000003199 nucleic acid amplification method Methods 0.000 claims 2
- 201000008968 osteosarcoma Diseases 0.000 claims 2
- 201000002528 pancreatic cancer Diseases 0.000 claims 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 2
- 208000000587 small cell lung carcinoma Diseases 0.000 claims 2
- 206010042863 synovial sarcoma Diseases 0.000 claims 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 2
- 108090000695 Cytokines Proteins 0.000 claims 1
- 102000004127 Cytokines Human genes 0.000 claims 1
- 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 claims 1
- 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 claims 1
- 101000623901 Homo sapiens Mucin-16 Proteins 0.000 claims 1
- 101001123448 Homo sapiens Prolactin receptor Proteins 0.000 claims 1
- 101000638154 Homo sapiens Transmembrane protease serine 2 Proteins 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- 108010002352 Interleukin-1 Proteins 0.000 claims 1
- 108090000177 Interleukin-11 Proteins 0.000 claims 1
- 108010065805 Interleukin-12 Proteins 0.000 claims 1
- 108090000176 Interleukin-13 Proteins 0.000 claims 1
- 108050003558 Interleukin-17 Proteins 0.000 claims 1
- 108010002350 Interleukin-2 Proteins 0.000 claims 1
- 108010002386 Interleukin-3 Proteins 0.000 claims 1
- 108090000978 Interleukin-4 Proteins 0.000 claims 1
- 108010002616 Interleukin-5 Proteins 0.000 claims 1
- 108090001005 Interleukin-6 Proteins 0.000 claims 1
- 108090001007 Interleukin-8 Proteins 0.000 claims 1
- 108010002335 Interleukin-9 Proteins 0.000 claims 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims 1
- 102100023123 Mucin-16 Human genes 0.000 claims 1
- 102100029000 Prolactin receptor Human genes 0.000 claims 1
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 1
- 102100031989 Transmembrane protease serine 2 Human genes 0.000 claims 1
- 108010087914 epidermal growth factor receptor VIII Proteins 0.000 claims 1
- 150000002431 hydrogen Chemical class 0.000 claims 1
- 108020003175 receptors Proteins 0.000 claims 1
- 208000015347 renal cell adenocarcinoma Diseases 0.000 claims 1
- 201000002510 thyroid cancer Diseases 0.000 claims 1
- 210000001685 thyroid gland Anatomy 0.000 claims 1
- 239000000203 mixture Substances 0.000 description 25
- 239000011230 binding agent Substances 0.000 description 20
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 12
- 229940024606 amino acid Drugs 0.000 description 4
- 235000001014 amino acid Nutrition 0.000 description 4
- 0 CC(C)[C@@](C(N[C@@](CCCNC(N)=O)C(C)=O)=O)NC(*(C)(C)N(C(CC1C)=O)C1=O)=O Chemical compound CC(C)[C@@](C(N[C@@](CCCNC(N)=O)C(C)=O)=O)NC(*(C)(C)N(C(CC1C)=O)C1=O)=O 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- OVSKIKFHRZPJSS-UHFFFAOYSA-N 2,4-D Chemical compound OC(=O)COC1=CC=C(Cl)C=C1Cl OVSKIKFHRZPJSS-UHFFFAOYSA-N 0.000 description 1
- ROEXBULBZKICBC-KRQJBFIFSA-N C[C@@H](C(O[C@@H](CC(N(C)c(cc(C/C(/C)=C/C=C/[C@H]([C@@](C[C@H](C)[C@@H](C)[C@@H]1C)(NC(O)=O)O)OC)cc2OC)c2Cl)=O)[C@]1(C)O)=O)N(C)C(c(cc1)cc(S(C)(=O)=O)c1NNC)=O Chemical compound C[C@@H](C(O[C@@H](CC(N(C)c(cc(C/C(/C)=C/C=C/[C@H]([C@@](C[C@H](C)[C@@H](C)[C@@H]1C)(NC(O)=O)O)OC)cc2OC)c2Cl)=O)[C@]1(C)O)=O)N(C)C(c(cc1)cc(S(C)(=O)=O)c1NNC)=O ROEXBULBZKICBC-KRQJBFIFSA-N 0.000 description 1
- LHKUAZUPONJFED-BJWVSRTKSA-N C[C@@H](C(O[C@@H](CC(N(C)c(cc(C/C(/C)=C/C=C/[C@H]1OC)cc2OC)c2Cl)=O)[C@@H](C)[C@@H](C)[C@H](C)[C@@H](C)C[C@]1(NC(O)=O)O)=O)NC Chemical compound C[C@@H](C(O[C@@H](CC(N(C)c(cc(C/C(/C)=C/C=C/[C@H]1OC)cc2OC)c2Cl)=O)[C@@H](C)[C@@H](C)[C@H](C)[C@@H](C)C[C@]1(NC(O)=O)O)=O)NC LHKUAZUPONJFED-BJWVSRTKSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021044152A JP2021113191A (ja) | 2015-03-27 | 2021-03-17 | メイタンシノイド誘導体、そのコンジュゲート、及び使用方法 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562139044P | 2015-03-27 | 2015-03-27 | |
| US62/139,044 | 2015-03-27 | ||
| US201562252239P | 2015-11-06 | 2015-11-06 | |
| US62/252,239 | 2015-11-06 | ||
| PCT/US2016/024343 WO2016160615A1 (en) | 2015-03-27 | 2016-03-25 | Maytansinoid derivatives, conjugates thereof, and methods of use |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021044152A Division JP2021113191A (ja) | 2015-03-27 | 2021-03-17 | メイタンシノイド誘導体、そのコンジュゲート、及び使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018516851A JP2018516851A (ja) | 2018-06-28 |
| JP2018516851A5 true JP2018516851A5 (enExample) | 2019-05-23 |
| JP6948950B2 JP6948950B2 (ja) | 2021-10-13 |
Family
ID=55650789
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017550548A Active JP6948950B2 (ja) | 2015-03-27 | 2016-03-25 | メイタンシノイド誘導体、そのコンジュゲート、及び使用方法 |
| JP2021044152A Withdrawn JP2021113191A (ja) | 2015-03-27 | 2021-03-17 | メイタンシノイド誘導体、そのコンジュゲート、及び使用方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021044152A Withdrawn JP2021113191A (ja) | 2015-03-27 | 2021-03-17 | メイタンシノイド誘導体、そのコンジュゲート、及び使用方法 |
Country Status (17)
| Country | Link |
|---|---|
| US (4) | US20160375147A1 (enExample) |
| EP (1) | EP3273998B1 (enExample) |
| JP (2) | JP6948950B2 (enExample) |
| KR (2) | KR20240142591A (enExample) |
| CN (2) | CN107995912A (enExample) |
| AU (1) | AU2016243527B2 (enExample) |
| BR (1) | BR112017020149A8 (enExample) |
| CA (1) | CA2978340C (enExample) |
| CL (1) | CL2017002422A1 (enExample) |
| CO (1) | CO2017010890A2 (enExample) |
| EA (1) | EA034950B1 (enExample) |
| IL (1) | IL254267B (enExample) |
| MX (2) | MX386328B (enExample) |
| PH (1) | PH12017501780A1 (enExample) |
| SG (1) | SG11201707148PA (enExample) |
| WO (1) | WO2016160615A1 (enExample) |
| ZA (1) | ZA201706040B (enExample) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112015022585B1 (pt) | 2013-03-15 | 2023-04-04 | Regeneron Pharmaceuticals, Inc | Composto, composição farmacêutica, conjugado droga-anticorpo, e, uso dos mesmos |
| JP6608823B2 (ja) | 2013-08-26 | 2019-11-20 | レゲネロン ファーマシューティカルス，インコーポレーテッド | マクロライドジアステレオマーを含む医薬組成物、その合成方法、及び治療上の使用 |
| KR20240142591A (ko) | 2015-03-27 | 2024-09-30 | 리제너론 파아마슈티컬스, 인크. | 메이탄시노이드 유도체, 이의 컨주게이트, 및 사용 방법 |
| EP3310800B1 (en) | 2015-06-19 | 2021-11-17 | Centurion BioPharma Corporation | Delivery systems for controlled drug release |
| JP6993958B2 (ja) | 2015-07-06 | 2022-02-04 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 多重特異性抗原結合分子およびその使用 |
| AU2017211120C1 (en) | 2016-01-25 | 2021-10-07 | Regeneron Pharmaceuticals, Inc. | Maytansinoid derivatives, conjugates thereof, and methods of use |
| EP3448891A1 (en) | 2016-04-28 | 2019-03-06 | Regeneron Pharmaceuticals, Inc. | Methods of making multispecific antigen-binding molecules |
| MY199468A (en) | 2016-09-23 | 2023-10-31 | Regeneron Pharma | Anti-steap2 antibodies, antibody-drug conjugates, and bispecific antigen-binding molecules that bind steap2 and cd3, and uses thereof |
| PT3515946T (pt) | 2016-09-23 | 2022-08-04 | Regeneron Pharma | Anticorpos anti-muc16 (mucin 16) |
| TWI782930B (zh) | 2016-11-16 | 2022-11-11 | 美商再生元醫藥公司 | 抗ｍｅｔ抗體，結合ｍｅｔ之雙特異性抗原結合分子及其使用方法 |
| MX2019006131A (es) | 2016-11-29 | 2019-08-21 | Regeneron Pharma | Metodos para tratar cancer de mama positivo para prlr. |
| CN110944718A (zh) | 2017-05-18 | 2020-03-31 | 里珍纳龙药品有限公司 | 环糊精蛋白质药物偶联物 |
| MA50546A (fr) | 2017-06-07 | 2020-09-16 | Regeneron Pharma | Compositions et méthodes pour l'internalisation d'enzymes |
| CA3080857A1 (en) | 2017-11-07 | 2019-05-16 | Regeneron Pharmaceuticals, Inc. | Hydrophilic linkers for antibody drug conjugates |
| US11572373B2 (en) * | 2017-11-30 | 2023-02-07 | Ladrx Corporation | Maytansinoid-based drug delivery systems |
| KR102871690B1 (ko) | 2018-04-30 | 2025-10-16 | 리제너론 파마슈티칼스 인코포레이티드 | Her2 및/또는 aplp2에 결합하는 항체 및 이중특이적 항원-결합 분자 및 접합체 그리고 이들의 용도 |
| AU2019269685B2 (en) | 2018-05-17 | 2025-12-04 | Regeneron Pharmaceuticals, Inc. | Anti-CD63 antibodies, conjugates, and uses thereof |
| WO2020057543A1 (zh) * | 2018-09-21 | 2020-03-26 | 中国人民解放军军事科学院军事医学研究院 | 基于芳硝基的连接子、含连接子的抗体偶联药物及连接子的用途 |
| JP2022523360A (ja) | 2019-02-21 | 2022-04-22 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | Ｍｅｔに結合する抗ｍｅｔ抗体および二特異性抗原結合分子を使用した眼癌の治療方法 |
| KR20220063185A (ko) | 2019-09-16 | 2022-05-17 | 리제너론 파마슈티칼스 인코포레이티드 | 면역-pet 영상화를 위한 방사성 표지된 met 결합 단백질 |
| US11814428B2 (en) * | 2019-09-19 | 2023-11-14 | Regeneron Pharmaceuticals, Inc. | Anti-PTCRA antibody-drug conjugates and uses thereof |
| WO2021097220A1 (en) | 2019-11-15 | 2021-05-20 | Seagen Inc. | Methods of treating her2 positive breast cancer with tucatinib in combination with an anti-her2 antibody-drug conjugate |
| CN113292574B (zh) * | 2020-02-21 | 2022-05-03 | 四川大学 | 一类手性多环的托品烷化合物及其制备方法和用途 |
| AU2021228225A1 (en) | 2020-02-28 | 2022-09-01 | Regeneron Pharmaceuticals, Inc. | Bispecific antigen binding molecules that bind HER2, and methods of use thereof |
| IL297027B2 (en) | 2020-04-16 | 2025-08-01 | Regeneron Pharma | Antibody-drug conjugates prepared using diels-alder conjugation methods |
| JP7767411B2 (ja) | 2020-10-22 | 2025-11-11 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 抗ｆｇｆｒ２抗体及びその使用方法 |
| CN116615257A (zh) | 2020-11-10 | 2023-08-18 | 瑞泽恩制药公司 | 硒抗体缀合物 |
Family Cites Families (82)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4307016A (en) | 1978-03-24 | 1981-12-22 | Takeda Chemical Industries, Ltd. | Demethyl maytansinoids |
| JPS5566585A (en) * | 1978-11-14 | 1980-05-20 | Takeda Chem Ind Ltd | Novel maytansinoid compound and its preparation |
| JPS55164686A (en) | 1979-06-11 | 1980-12-22 | Takeda Chem Ind Ltd | Novel maytansinoid compound and its preparation |
| US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
| CA2026147C (en) | 1989-10-25 | 2006-02-07 | Ravi J. Chari | Cytotoxic agents comprising maytansinoids and their therapeutic use |
| US5714586A (en) | 1995-06-07 | 1998-02-03 | American Cyanamid Company | Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates |
| US7087411B2 (en) | 1999-06-08 | 2006-08-08 | Regeneron Pharmaceuticals, Inc. | Fusion protein capable of binding VEGF |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| US20070258987A1 (en) | 2000-11-28 | 2007-11-08 | Seattle Genetics, Inc. | Recombinant Anti-Cd30 Antibodies and Uses Thereof |
| EP1258255A1 (en) | 2001-05-18 | 2002-11-20 | Boehringer Ingelheim International GmbH | Conjugates of an antibody to CD44 and a maytansinoid |
| US20050276812A1 (en) | 2004-06-01 | 2005-12-15 | Genentech, Inc. | Antibody-drug conjugates and methods |
| US20090068178A1 (en) | 2002-05-08 | 2009-03-12 | Genentech, Inc. | Compositions and Methods for the Treatment of Tumor of Hematopoietic Origin |
| US20110250133A1 (en) | 2003-01-13 | 2011-10-13 | Bracco Imaging S.P.A. | Gastrin releasing peptide compounds |
| US8088387B2 (en) | 2003-10-10 | 2012-01-03 | Immunogen Inc. | Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates |
| US7276497B2 (en) | 2003-05-20 | 2007-10-02 | Immunogen Inc. | Cytotoxic agents comprising new maytansinoids |
| EP3679951A1 (en) | 2003-06-27 | 2020-07-15 | Amgen Fremont Inc. | Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof |
| GB0316294D0 (en) | 2003-07-11 | 2003-08-13 | Polytherics Ltd | Conjugated biological molecules and their preparation |
| TW200539855A (en) | 2004-03-15 | 2005-12-16 | Wyeth Corp | Calicheamicin conjugates |
| JP2008521828A (ja) | 2004-11-29 | 2008-06-26 | シアトル ジェネティックス， インコーポレイテッド | 操作された抗体およびイムノコンジュゲート |
| DK1819359T3 (en) | 2004-12-09 | 2015-04-20 | Janssen Biotech Inc | ANTI-integrin immunoconjugates, processes for their preparation and their use |
| EP1912677B1 (en) | 2005-06-20 | 2013-10-02 | Psma Development Company, L.L.C. | PSMA antibody-drug conjugates |
| EP2135881B1 (en) | 2005-06-20 | 2011-09-07 | Genentech, Inc. | Antibodies binding to the tumour associated antigen TAT10772 for the diagnosis and treatment of tumor |
| EP1913002B9 (en) | 2005-08-09 | 2012-04-25 | Millennium Pharmaceuticals, Inc. | Method of acylating maytansinol with chiral amino acids |
| KR101352222B1 (ko) | 2005-12-22 | 2014-02-04 | 백스터 인터내셔널 인코포레이티드 | 의료용 제품에서 비-내독소 발열성 오염물을 보다 잘검출할 수 있는 개선된 단핵구 활성화 시험 |
| US7750116B1 (en) | 2006-02-18 | 2010-07-06 | Seattle Genetics, Inc. | Antibody drug conjugate metabolites |
| PT2845866T (pt) | 2006-10-27 | 2017-08-09 | Genentech Inc | Anticorpos e imunoconjugados e utilizações dos mesmos |
| NO347649B1 (no) | 2006-12-14 | 2024-02-12 | Regeneron Pharma | Humant antistoff eller antistoff fragment som spesifikt binder human deltaliknende ligand 4 (hDII4), nukleinsyremolekyl som koder for slike og vektor og vert-vektorsystemer, samt fremgangsmåte for fremstilling, sammensetning og anvendelse. |
| WO2008122039A2 (en) | 2007-04-02 | 2008-10-09 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Selenocysteine mediated hybrid antibody molecules |
| AU2008251608B2 (en) | 2007-05-08 | 2014-03-27 | Genentech, Inc. | Cysteine engineered anti-MUC16 antibodies and antibody drug conjugates |
| DK2167963T3 (da) | 2007-05-23 | 2019-06-24 | Ventana Med Syst Inc | Polymerbærere til immunhistokemi og in situ-hybridisering |
| HUE035182T2 (hu) | 2008-03-18 | 2018-05-02 | Genentech Inc | Anti-HER2 antitest-hatóanyag-konjugátum és pertuzumab kombinációi |
| BRPI0911442A2 (pt) | 2008-04-30 | 2019-03-12 | Immunogen, Inc. | conjugados potentes e ligantes hidrofílicos |
| EP2326349B1 (en) | 2008-07-21 | 2015-02-25 | Polytherics Limited | Novel reagents and method for conjugating biological molecules |
| WO2010100430A1 (en) | 2009-03-04 | 2010-09-10 | Polytherics Limited | Conjugated proteins and peptides |
| JO3182B1 (ar) | 2009-07-29 | 2018-03-08 | Regeneron Pharma | مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2 |
| AU2010283632B2 (en) | 2009-08-10 | 2016-08-25 | Ucl Business Plc | Reversible covalent linkage of functional molecules |
| AR078470A1 (es) | 2009-10-02 | 2011-11-09 | Sanofi Aventis | Anticuerpos que se unen especificamente al receptor epha2 |
| UY32913A (es) | 2009-10-02 | 2011-04-29 | Sanofi Aventis | Nuevos maitansinoides y el uso de dichos maitansinoides para preparar conjugados con un anticuero |
| CN102596922A (zh) | 2009-10-06 | 2012-07-18 | 免疫基因公司 | 有效的缀合物和亲水性连接体 |
| US8501692B2 (en) | 2009-12-14 | 2013-08-06 | The Regents Of The University Of Michigan | Compositions and methods for altering cocaine esterase activity |
| TWI540136B (zh) | 2010-04-15 | 2016-07-01 | 梅迪繆思有限公司 | 吡咯并苯并二氮呯及其共軛物 |
| US20130244905A1 (en) | 2010-07-06 | 2013-09-19 | Ed Grabczyk | Reporter for RNA Polymerase II Termination |
| CA3250882A1 (en) | 2010-08-02 | 2025-11-29 | Regeneron Pharamaceuticals, Inc. | Mice that Make Binding Proteins Comprising VL Domains |
| DK2611785T3 (da) | 2010-09-01 | 2014-08-25 | Bayer Ip Gmbh | N-(tetrazol-5yl)- og n- (triazol-5-yl) arylcarboxylsyreamider og deres anvendelse som herbicider |
| AU2011320318B9 (en) | 2010-10-29 | 2015-11-19 | Immunogen, Inc. | Non-antagonistic EGFR-binding molecules and immunoconjugates thereof |
| CN103269712B (zh) | 2010-11-03 | 2016-09-21 | 伊缪诺金公司 | 包含新型安丝菌素衍生物的细胞毒性剂 |
| JP6215194B2 (ja) | 2011-05-16 | 2017-10-18 | コーニンクレッカ フィリップス エヌ ヴェＫｏｎｉｎｋｌｉｊｋｅ Ｐｈｉｌｉｐｓ Ｎ．Ｖ． | 生体直交型薬物活性化 |
| MX345538B (es) | 2011-05-27 | 2017-02-03 | Ambrx Inc | Composiciones que contienen, metodos que incluyen, y usos de derivados de dolastatina enlazados a aminoacidos no naturales. |
| US8815226B2 (en) | 2011-06-10 | 2014-08-26 | Mersana Therapeutics, Inc. | Protein-polymer-drug conjugates |
| JP6209159B2 (ja) * | 2011-06-21 | 2017-10-04 | イミュノジェン・インコーポレーテッド | ペプチドリンカーを有する新規メイタンシノイド誘導体およびその結合体 |
| EA026643B1 (ru) | 2011-10-14 | 2017-04-28 | Сиэтл Дженетикс, Инк. | Пирролбензодиазепины и конъюгаты направленного действия |
| CA2850096C (en) | 2011-10-14 | 2018-07-03 | Spirogen Sarl | Synthesis method and intermediates useful in the preparation of pyrrolobenzodiazepines |
| WO2013055990A1 (en) | 2011-10-14 | 2013-04-18 | Seattle Genetics, Inc. | Pyrrolobenzodiazepines and targeted conjugates |
| US9399073B2 (en) | 2011-10-14 | 2016-07-26 | Seattle Genetics, Inc. | Pyrrolobenzodiazepines |
| WO2013068874A1 (en) | 2011-11-11 | 2013-05-16 | Pfizer Inc. | Antibody-drug conjugates |
| CA2857398A1 (en) | 2011-12-05 | 2013-06-13 | Igenica Biotherapeutics, Inc. | Antibody-drug conjugates and related compounds, compositions, and methods |
| GB201210770D0 (en) | 2012-06-18 | 2012-08-01 | Polytherics Ltd | Novel conjugation reagents |
| US20150125473A1 (en) | 2012-06-19 | 2015-05-07 | Polytherics Limited | Novel process for preparation of antibody conjugates and novel antibody conjugates |
| CN105142672B (zh) | 2012-10-23 | 2019-04-05 | 西纳福克斯股份有限公司 | 经修饰的抗体、抗体-缀合物及其制备方法 |
| NO2789793T3 (enExample) | 2012-10-24 | 2018-01-27 | ||
| JP6133431B2 (ja) * | 2012-11-24 | 2017-05-24 | ハンジョウ ディーエーシー バイオテック シーオー．，エルティディ．Ｈａｎｇｚｈｏｕ Ｄａｃ Ｂｉｏｔｅｃｈ Ｃｏ．，Ｌｔｄ． | 親水性連結体及び薬物分子と細胞結合分子との共役反応における親水性連結体の使用 |
| TW201425336A (zh) | 2012-12-07 | 2014-07-01 | Amgen Inc | Ｂｃｍａ抗原結合蛋白質 |
| CN103254213B (zh) | 2012-12-21 | 2015-02-25 | 百奥泰生物科技(广州)有限公司 | 类美登素酯的制备方法及用于所述方法的组合物 |
| CN104650113A (zh) | 2012-12-21 | 2015-05-27 | 百奥泰生物科技(广州)有限公司 | 类美登素衍生物及其制备方法和用途 |
| BR112015022585B1 (pt) * | 2013-03-15 | 2023-04-04 | Regeneron Pharmaceuticals, Inc | Composto, composição farmacêutica, conjugado droga-anticorpo, e, uso dos mesmos |
| CN103254311B (zh) | 2013-05-09 | 2015-05-13 | 齐鲁制药有限公司 | 一种制备抗体-美登素类生物碱药物偶联物的方法 |
| WO2014194030A2 (en) | 2013-05-31 | 2014-12-04 | Immunogen, Inc. | Conjugates comprising cell-binding agents and cytotoxic agents |
| US11229711B2 (en) | 2013-06-06 | 2022-01-25 | Magenta Therapeutics, Inc. | Linkers for antibody-drug conjugates and related compounds, compositions, and methods of use |
| WO2014197866A1 (en) | 2013-06-06 | 2014-12-11 | Igenica Biotherapeutics, Inc. | Modified antibodies and related compounds, compositions, and methods of use |
| US20140363454A1 (en) | 2013-06-06 | 2014-12-11 | Igenica Biotherapeutics, Inc. | Antibody-Drug Conjugates, Compositions and Methods of Use |
| EP3003390B1 (en) | 2013-06-06 | 2021-07-07 | Pierre Fabre Médicament | Anti-c10orf54 antibodies and uses thereof |
| TWI641620B (zh) | 2013-08-21 | 2018-11-21 | 再生元醫藥公司 | 抗－ｐｒｌｒ抗體及其用途 |
| US9545451B2 (en) | 2013-08-21 | 2017-01-17 | Regeneron Pharmaceuticals, Inc. | Anti-PRLR antibodies and methods for killing PRLR-expressing cells |
| JP6608823B2 (ja) * | 2013-08-26 | 2019-11-20 | レゲネロン ファーマシューティカルス，インコーポレーテッド | マクロライドジアステレオマーを含む医薬組成物、その合成方法、及び治療上の使用 |
| WO2015081281A1 (en) | 2013-11-26 | 2015-06-04 | Segway Orthopaedics, Inc. | Surgical blade with viewing aperture |
| CA3178867A1 (en) | 2013-11-27 | 2015-06-04 | Redwood Bioscience, Inc. | Hydrazinyl-pyrrolo compounds and methods for producing a conjugate |
| US9562059B2 (en) | 2013-12-02 | 2017-02-07 | Hong Kong Baptist University | Anticancer maytansinoids with two fused macrocyclic rings |
| US9951141B2 (en) | 2014-06-02 | 2018-04-24 | Regeneron Pharmaceuticals, Inc. | Antibody-drug conjugates, their preparation and their therapeutic use |
| KR20240142591A (ko) | 2015-03-27 | 2024-09-30 | 리제너론 파아마슈티컬스, 인크. | 메이탄시노이드 유도체, 이의 컨주게이트, 및 사용 방법 |
| AU2017211120C1 (en) | 2016-01-25 | 2021-10-07 | Regeneron Pharmaceuticals, Inc. | Maytansinoid derivatives, conjugates thereof, and methods of use |
| MY199468A (en) | 2016-09-23 | 2023-10-31 | Regeneron Pharma | Anti-steap2 antibodies, antibody-drug conjugates, and bispecific antigen-binding molecules that bind steap2 and cd3, and uses thereof |
| US11814428B2 (en) | 2019-09-19 | 2023-11-14 | Regeneron Pharmaceuticals, Inc. | Anti-PTCRA antibody-drug conjugates and uses thereof |
-
2016
- 2016-03-25 KR KR1020247030839A patent/KR20240142591A/ko active Pending
- 2016-03-25 CN CN201680030443.2A patent/CN107995912A/zh active Pending
- 2016-03-25 US US15/081,759 patent/US20160375147A1/en not_active Abandoned
- 2016-03-25 JP JP2017550548A patent/JP6948950B2/ja active Active
- 2016-03-25 AU AU2016243527A patent/AU2016243527B2/en active Active
- 2016-03-25 BR BR112017020149A patent/BR112017020149A8/pt not_active Application Discontinuation
- 2016-03-25 EP EP16714199.3A patent/EP3273998B1/en active Active
- 2016-03-25 WO PCT/US2016/024343 patent/WO2016160615A1/en not_active Ceased
- 2016-03-25 MX MX2017012380A patent/MX386328B/es unknown
- 2016-03-25 EA EA201700464A patent/EA034950B1/ru unknown
- 2016-03-25 CA CA2978340A patent/CA2978340C/en active Active
- 2016-03-25 CN CN202210829028.0A patent/CN115645543A/zh active Pending
- 2016-03-25 KR KR1020177030678A patent/KR102708103B1/ko active Active
- 2016-03-25 SG SG11201707148PA patent/SG11201707148PA/en unknown
-
2017
- 2017-09-01 IL IL254267A patent/IL254267B/en active IP Right Grant
- 2017-09-05 ZA ZA2017/06040A patent/ZA201706040B/en unknown
- 2017-09-26 CL CL2017002422A patent/CL2017002422A1/es unknown
- 2017-09-27 PH PH12017501780A patent/PH12017501780A1/en unknown
- 2017-09-27 MX MX2021008101A patent/MX2021008101A/es unknown
- 2017-10-26 CO CONC2017/0010890A patent/CO2017010890A2/es unknown
-
2019
- 2019-12-12 US US16/712,941 patent/US20200385402A1/en not_active Abandoned
-
2021
- 2021-03-17 JP JP2021044152A patent/JP2021113191A/ja not_active Withdrawn
- 2021-11-16 US US17/528,144 patent/US12297207B2/en active Active
-
2025
- 2025-03-28 US US19/093,440 patent/US20250223299A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018516851A5 (enExample) | ||
| KR102708103B1 (ko) | 메이탄시노이드 유도체, 이의 컨주게이트, 및 사용 방법 | |
| JP6934010B2 (ja) | メイタンシノイド誘導体、そのコンジュゲート、及び使用方法 | |
| JP6133431B2 (ja) | 親水性連結体及び薬物分子と細胞結合分子との共役反応における親水性連結体の使用 | |
| JP6417421B2 (ja) | 荷電連結体及び共役体のためのその使用 | |
| KR20250004952A (ko) | 캄프토테신 접합체 | |
| AU2012244675B2 (en) | Novel binder-drug conjugates (ADCs) and their use | |
| JPWO2019240288A1 (ja) | 抗体に対する親和性物質、および生体直交性官能基を有する化合物またはその塩 | |
| JP7573262B2 (ja) | 細胞結合分子の共役のための架橋連結体 | |
| JP2020506951A5 (enExample) | ||
| RU2014128467A (ru) | Новые коньюгаты связывающее соединение-активное соединение (adc) и их применение | |
| RU2018145728A (ru) | Агонист глюкокортикоидного рецептора и его иммуноконъюгаты | |
| RU2014146951A (ru) | Конъюгаты типа лиганд dr5-лекарственное средство | |
| JP2015500287A (ja) | 抗体−薬物のコンジュゲート、ならびに関連する化合物、組成物および方法 | |
| TWI838358B (zh) | 疏水性奧瑞他汀(auristatin)f化合物及其結合物 | |
| JP6908964B2 (ja) | Ｐｓｍａリガンドコンジュゲートによる併用療法 | |
| WO2015153857A1 (en) | Methods for enhancing the efficacy of a tumor-directed immune response | |
| JPWO2021177438A5 (enExample) | ||
| TW201627286A (zh) | 放射性醫藥複合物 | |
| JP2022540395A (ja) | 細胞結合性分子－チューブリシン誘導体共役体及びその調製方法 | |
| JP2019536780A (ja) | Ｍｅｔ抗体薬物複合体 | |
| JP7774882B2 (ja) | 新規な連結体及び生体分子と薬物との特異的共役におけるその使用 | |
| JP2018168068A (ja) | 抗ポドプラニン抗体及び抗体薬物複合体 | |
| JP2016540826A5 (enExample) | ||
| JPWO2020089687A5 (enExample) |